肠道菌群与乙型肝炎肝硬化

李艳男; 李长政

doi:10.12449/JCH250324

肠道菌群与乙型肝炎肝硬化

DOI: 10.12449/JCH250324

李艳男¹,
李长政^2, , ,

1.
锦州医科大学火箭军特色医学中心研究生培养基地消化科，北京 100088
2.
中国人民解放军火箭军特色医学中心消化科，北京 100088

基金项目:

中国人民解放军火箭军特色医学中心自主科研项目 (25FC003)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：李艳男负责设计论文框架，撰写论文；李长政负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
李长政， licz435@163.com （ORCID： 0009-0001-3771-6155）

计量
- 文章访问数: 182
- HTML全文浏览量: 78
- PDF下载量: 30
- 被引次数: 0
出版历程
- 收稿日期: 2024-06-07
- 录用日期: 2024-07-24
- 出版日期: 2025-03-25

Gut microbiota in hepatitis B cirrhosis

Yannan LI¹,
Changzheng LI^{2
, ,
,}

1.
Department of Gastroenterology，Training Base for Postgraduate Students，PLA Rocket Force Characteristic Medical Center of Jinzhou Medical University，Beijing 100088，China
2.
Department of Gastroenterology，PLA Rocket Force Characteristic Medical Center，Beijing 100088，China

Research funding:

Independent Research Project of Chinese People’s Liberation Army Rocket Force Characteristic Medical Center (25FC003)

More Information

Corresponding author: LI Changzheng， licz435@163.com （ORCID： 0009-0001-3771-6155）

摘要

摘要: 乙型肝炎肝硬化是我国肝硬化最主要组成部分，由肝炎发展到肝硬化后患者病死率明显增加。大量研究证实肠道菌群会影响乙型肝炎肝硬化病程进展，包括对炎症反应和肠道免疫调节的影响、对HBV的抑制、产生氨类物质等。本文就乙型肝炎肝硬化肠道菌群变化的研究进展进行综述，归纳通过干预肠道菌群治疗乙型肝炎肝硬化的新思路。
- 乙型肝炎 /
- 肝硬化 /
- 胃肠道微生物组 /
- RNA，核糖体， 16S
Abstract: Hepatitis B cirrhosis is the most significant component of liver cirrhosis in China， and there is a significant increase in the mortality rate of patients after progression from hepatitis to liver cirrhosis. A large number of studies have shown that gut microbiota may influence the progression of hepatitis B cirrhosis， including the impact on the regulation of inflammatory response and intestinal immunity， the inhibition of HBV， and the production of ammonia-like substances. This article reviews the research advances in the changes in gut microbiota in hepatitis B cirrhosis patients and explores new ideas for the treatment of hepatitis B cirrhosis by intervening in gut microbiota.
- Hepatitis B /
- Liver Cirrhosis /
- Gastrointestinal Microbiome /
- RNA， Ribosomal， 16S

HTML全文

表 1 影响乙型肝炎肝硬化患者的肠道菌群

Table 1. Influencing the gut microbiota of hepatitis B cirrhosis patients

影响因素	有益菌	致病菌
炎症反应	双歧杆菌属、乳酸杆菌属、鼠李糖乳杆菌属、粪链球菌属、毛螺菌科、瘤胃球菌科	大肠杆菌、耐热链球菌、粪肠球菌、大肠埃希菌、拟杆菌、肠杆菌科、韦荣球菌属、肠球菌
肠道免疫调节	梭状芽孢杆菌、拟杆菌、肠球菌、乳酸杆菌、双歧杆菌	肠杆菌、肠球菌
HBV复制	毛螺菌科、瘤胃球菌科、乳酸杆菌、双歧杆菌	梭状芽孢杆菌、拟杆菌
产氨	梭杆菌、巨杆菌、粪杆菌	梭状芽孢杆菌属-Ⅺ、韦荣球菌属、肠球菌属、普雷沃菌属

下载: 导出CSV

参考文献(29)

[1]	TRANAH TH, EDWARDS LA, SCHNABL B, et al. Targeting the gut-liver-immune axis to treat cirrhosis[J]. Gut, 2021, 70( 5): 982- 994. DOI: 10.1136/gutjnl-2020-320786.
[2]	SHEN Y, WU SD, CHEN Y, et al. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response[J]. Gut Microbes, 2023, 15( 1): 2155018. DOI: 10.1080/19490976.2022.2155018.
[3]	ZENG YB, CHEN SJ, FU Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Viral Hepat, 2020, 27( 2): 143- 155. DOI: 10.1111/jvh.13216.
[4]	CHEN B, HUANG H, PAN CQ. The role of gut microbiota in hepatitis B disease progression and treatment[J]. J Viral Hepat, 2022, 29( 2): 94- 106. DOI: 10.1111/jvh.13595.
[5]	SUNG CM, LIN YF, CHEN KF, et al. Predicting clinical outcomes of cirrhosis patients with hepatic encephalopathy from the fecal microbiome[J]. Cell Mol Gastroenterol Hepatol, 2019, 8( 2): 301- 318. e 2. DOI: 10.1016/j.jcmgh.2019.04.008.
[6]	GUO ZW, ZHANG JX, LI S, et al. Research advances in intestinal flora and the development and prognosis of chronic hepatitis B[J]. J Clin Hepatol, 2022, 38( 5): 1137- 1142. DOI: 10.3969/j.issn.1001-5256.2022.05.034. 郭紫薇, 张嘉鑫, 李硕, 等. 肠道菌群与慢性乙型肝炎发生发展及预后的关系[J]. 临床肝胆病杂志, 2022, 38( 5): 1137- 1142. DOI: 10.3969/j.issn.1001-5256.2022.05.034.
[7]	LI YG, YU ZJ, LI A, et al. Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: Molecular mechanisms and therapeutic inventions[J]. World J Gastroenterol, 2022, 28( 28): 3555- 3572. DOI: 10.3748/wjg.v28.i28.3555.
[8]	MILOSEVIC I, RUSSO E, VUJOVIC A, et al. Microbiota and viral hepatitis: State of the art of a complex matter[J]. World J Gastroenterol, 2021, 27( 33): 5488- 5501. DOI: 10.3748/wjg.v27.i33.5488.
[9]	LIU SY, YANG XL. Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer[J]. Front Cell Infect Microbiol, 2023, 13: 1140126. DOI: 10.3389/fcimb.2023.1140126.
[10]	WU LL, HUANG TS, SHYU YC, et al. Gut microbiota in the innate immunity against hepatitis B virus-implication in age-dependent HBV clearance[J]. Curr Opin Virol, 2021, 49: 194- 202. DOI: 10.1016/j.coviro.2021.06.006.
[11]	ZHU RR, LIU LW, ZHANG GZ, et al. The pathogenesis of gut microbiota in hepatic encephalopathy by the gut-liver-brain axis[J]. Biosci Rep, 2023, 43( 6): BSR20222524. DOI: 10.1042/BSR20222524.
[12]	KOH A, de VADDER F, KOVATCHEVA-DATCHARY P, et al. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites[J]. Cell, 2016, 165( 6): 1332- 1345. DOI: 10.1016/j.cell.2016.05.041.
[13]	WU S, CHEN SJ, LIN JP, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis[J]. Ann Hepatol, 2022, 27( 2): 100676. DOI: 10.1016/j.aohep.2022.100676.
[14]	PANT K, MISHRA AK, PRADHAN SM, et al. Butyrate inhibits HBV replication and HBV-induced hepatoma cell proliferation via modulating SIRT-1/Ac-p53 regulatory axis[J]. Mol Carcinog, 2019, 58( 4): 524- 532. DOI: 10.1002/mc.22946.
[15]	CAI JW, RIMAL B, JIANG CT, et al. Bile acid metabolism and signaling, the microbiota, and metabolic disease[J]. Pharmacol Ther, 2022, 237: 108238. DOI: 10.1016/j.pharmthera.2022.108238.
[16]	WANG XL, CHEN L, WANG H, et al. Modulation of bile acid profile by gut microbiota in chronic hepatitis B[J]. J Cell Mol Med, 2020, 24( 4): 2573- 2581. DOI: 10.1111/jcmm.14951.
[17]	ROAGER HM, LICHT TR. Microbial tryptophan catabolites in health and disease[J]. Nat Commun, 2018, 9( 1): 3294. DOI: 10.1038/s41467-018-05470-4.
[18]	WANG YX, PAN CQ, XING HC. Advances in gut microbiota of viral hepatitis cirrhosis[J]. Biomed Res Int, 2019, 2019: 9726786. DOI: 10.1155/2019/9726786.
[19]	YOSHIO S, SUGIYAMA M, SHOJI H, et al. Indoleamine-2, 3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B[J]. Hepatology, 2016, 63( 1): 83- 94. DOI: 10.1002/hep.28282.
[20]	SUN X, PAN CQ, XING H. Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection[J]. Hepatol Int, 2021, 15( 5): 1053- 1067. DOI: 10.1007/s12072-021-10230-6.
[21]	LANG PA, CONTALDO C, GEORGIEV P, et al. Aggravation of viral hepatitis by platelet-derived serotonin[J]. Nat Med, 2008, 14( 7): 756- 761. DOI: 10.1038/nm1780.
[22]	KWAK DS, JUN DW, SEO JG, et al. Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease[J]. Eur J Gastroenterol Hepatol, 2014, 26( 12): 1353- 1359. DOI: 10.1097/MEG.0000000000000214.
[23]	LIU YH, CHEN KF, LI FY, et al. Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice[J]. Hepatology, 2020, 71( 6): 2050- 2066. DOI: 10.1002/hep.30975.
[24]	LEE DK, KANG JY, SHIN HS, et al. Antiviral activity of Bifidobacterium adolescentis SPM0212 against hepatitis B virus[J]. Arch Pharm Res, 2013, 36( 12): 1525- 1532. DOI: 10.1007/s12272-013-0141-3.
[25]	BAJAJ JS, KASSAM Z, FAGAN A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial[J]. Hepatology, 2017, 66( 6): 1727- 1738. DOI: 10.1002/hep.29306.
[26]	WEI Q, YANG JN, HE XL, et al. Role and potential mechanism of fecal microbiota transplantation in treatment of chronic hepatitis B[J]. Chin J Pathophysiol, 2020, 36( 10): 1833- 1843. DOI: 10.3969/j.issn.1000-4718.2020.10.015. 魏琦, 杨静楠, 何学良, 等. 粪便菌群移植在慢性乙肝治疗中的作用及机制[J]. 中国病理生理杂志, 2020, 36( 10): 1833- 1843. DOI: 10.3969/j.issn.1000-4718.2020.10.015.
[27]	ACHARYA C, BAJAJ JS. Altered microbiome in patients with cirrhosis and complications[J]. Clin Gastroenterol Hepatol, 2019, 17( 2): 307- 321. DOI: 10.1016/j.cgh.2018.08.008.
[28]	TREBICKA J, MACNAUGHTAN J, SCHNABL B, et al. The microbiota in cirrhosis and its role in hepatic decompensation[J]. J Hepatol, 2021, 75( Suppl 1): s67- s81. DOI: 10.1016/j.jhep.2020.11.013.
[29]	PONZIANI FR, ZOCCO MA, D’AVERSA F, et al. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation[J]. World J Gastroenterol, 2017, 23( 25): 4491- 4499. DOI: 10.3748/wjg.v23.i25.4491.